Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation

Ulf W Tunn,1 Damian Gruca,2 Peter Bacher3 1Urological Department, Prostate Center, Offenbach, Germany; 2AbbVie Deutschland GmbH and Co, KG, Ludwigshafen, Germany; 3AbbVie, North Chicago, IL, USA Abstract: For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leupror...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tunn UW, Gruca D, Bacher P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Androgen Deprivation Therapy GnRH agonist Leuprorelin acetate prostate cancer Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/ba306e3cef4144209d7f8a881f32d087
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba306e3cef4144209d7f8a881f32d087
record_format	dspace
spelling	oai:doaj.org-article:ba306e3cef4144209d7f8a881f32d0872021-12-02T01:50:09ZSix-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation1178-1998https://doaj.org/article/ba306e3cef4144209d7f8a881f32d0872013-04-01T00:00:00Zhttps://www.dovepress.com/six-month-leuprorelin-acetate-depot-formulations-in-advanced-prostate--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ulf W Tunn,1 Damian Gruca,2 Peter Bacher3 1Urological Department, Prostate Center, Offenbach, Germany; 2AbbVie Deutschland GmbH and Co, KG, Ludwigshafen, Germany; 3AbbVie, North Chicago, IL, USA Abstract: For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this therapy; however, their indicated treatment duration of 1 to 4 months was still not long enough to satisfy all medical needs. For this reason some manufacturers developed new injectable formulations that provide testosterone suppression for 6 months. This review article assesses key publications in order to compare these long-acting, commercially available, LA depot formulations and their clinical performance. The literature search identified 14 publications; by excluding reviews, duplications, and non-English articles, only three original papers describing clinical trial remained for review: two focused on microsphere-based LA formulations with either a 30 mg or 45 mg dose and one focused on a gel-based leuprorelin acetate with a 45 mg dose. All products were tested in individual clinical trials and have demonstrated their efficacy and safety. Keywords: androgen deprivation therapy, GnRH agonist, leuprorelin acetate, prostate cancer, leuprolide acetateTunn UWGruca DBacher PDove Medical PressarticleAndrogen Deprivation TherapyGnRH agonistLeuprorelin acetateprostate cancerGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 457-464 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Androgen Deprivation Therapy GnRH agonist Leuprorelin acetate prostate cancer Geriatrics RC952-954.6
spellingShingle	Androgen Deprivation Therapy GnRH agonist Leuprorelin acetate prostate cancer Geriatrics RC952-954.6 Tunn UW Gruca D Bacher P Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
description	Ulf W Tunn,1 Damian Gruca,2 Peter Bacher3 1Urological Department, Prostate Center, Offenbach, Germany; 2AbbVie Deutschland GmbH and Co, KG, Ludwigshafen, Germany; 3AbbVie, North Chicago, IL, USA Abstract: For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this therapy; however, their indicated treatment duration of 1 to 4 months was still not long enough to satisfy all medical needs. For this reason some manufacturers developed new injectable formulations that provide testosterone suppression for 6 months. This review article assesses key publications in order to compare these long-acting, commercially available, LA depot formulations and their clinical performance. The literature search identified 14 publications; by excluding reviews, duplications, and non-English articles, only three original papers describing clinical trial remained for review: two focused on microsphere-based LA formulations with either a 30 mg or 45 mg dose and one focused on a gel-based leuprorelin acetate with a 45 mg dose. All products were tested in individual clinical trials and have demonstrated their efficacy and safety. Keywords: androgen deprivation therapy, GnRH agonist, leuprorelin acetate, prostate cancer, leuprolide acetate
format	article
author	Tunn UW Gruca D Bacher P
author_facet	Tunn UW Gruca D Bacher P
author_sort	Tunn UW
title	Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
title_short	Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
title_full	Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
title_fullStr	Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
title_full_unstemmed	Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
title_sort	six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/ba306e3cef4144209d7f8a881f32d087
work_keys_str_mv	AT tunnuw sixmonthleuprorelinacetatedepotformulationsinadvancedprostatecanceraclinicalevaluation AT grucad sixmonthleuprorelinacetatedepotformulationsinadvancedprostatecanceraclinicalevaluation AT bacherp sixmonthleuprorelinacetatedepotformulationsinadvancedprostatecanceraclinicalevaluation
_version_	1718402863923724288

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation

Ejemplares similares